Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Jadhav has completed his B.Pharmacy and is having 30+ years of rich experience in operation management in pharmaceutical Industry
No safety signals related to the vaccine candidate were identified
Plans underway to expand screening capacity by 50% for greater accessibility
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Subscribe To Our Newsletter & Stay Updated
